Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (6094)	4/4/2002 9:22:07 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

quid, I didn't know about this issue when I first posted about the ovarian ca test - I bought some quickly because I saw the article in the Lancet when it first came out and before there was any PR from the company. This "field of use" issue has been discussed some on the CIPH thread. There's litigation, so things are pretty murky. However there's plenty of opportunity in the life sciences/drug discovery markets for CIPH to get much bigger - look at AFFX. It's also not clear that once you find which are the proteins that actually matter, you wouldn't use a cheap IGEN-type test for screening instead of this comparatively expensive test. There's presumably also some IP value in just figuring out what proteins to screen for - they could presumably use this to get a royalty on any actual tests. They've about doubled revenue in each of the last two years - it's now up to around $19m. Their technology seems to me to be in a fairly sweet spot, but I can't pretend to have a good grasp of the field they are playing in. Maybe tuck might have some comments? Peter